MEI Pharma, Inc.

Equities

MEIP

US55279B3015

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 04:30:00 2024-04-26 pm EDT			5-day change	1st Jan Change
3.05 ^USD	-1.61%		-6.15%	-47.41%

Apr. 11	MEI Pharma, Inc. Announces Strategic Plan to Leverage Recent Positive Voruciclib and ME-344 Clinical Data	CI
Apr. 11	MEI Pharma, Inc. Reports Initial Data from Clinical Study Evaluating ME-344 in Combination with Bevacizumab (Avastin®) in Relapsed Metastatic Colorectal Cancer Patients	CI

MEI Pharma, Inc. Reports Earnings Results for the Full Year Ended June 30, 2023

September 26, 2023 at 04:02 pm EDT

MEI Pharma, Inc. reported earnings results for the full year ended June 30, 2023. For the full year, the company reported sales was USD 48.82 million compared to USD 40.7 million a year ago. Net loss was USD 31.84 million compared to USD 54.45 million a year ago.

Basic loss per share from continuing operations was USD 4.78 compared to USD 8.75 a year ago. Diluted loss per share from continuing operations was USD 4.78 compared to USD 9.99 a year ago.

Latest news about MEI Pharma, Inc.

MEI Pharma, Inc. Announces Strategic Plan to Leverage Recent Positive Voruciclib and ME-344 Clinical Data	Apr. 11	CI
MEI Pharma, Inc. Reports Initial Data from Clinical Study Evaluating ME-344 in Combination with Bevacizumab (Avastin®) in Relapsed Metastatic Colorectal Cancer Patients	Apr. 11	CI
MEI Pharma, Inc. Reports Update from Clinical Study Evaluating Oral Cdk9 Inhibitor Voruciclib in Combination with Venetoclax in Patients with Relapsed and Refractory Acute Myeloid Leukemia	Mar. 26	CI
Stifel Adjusts Price Target on MEI Pharma to $7 From $8, Keeps Hold Rating	Feb. 14	MT
MEI Pharma, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended December 31, 2023	Feb. 13	CI
MEI Pharma Reports Clinical Data on Oral CDK9 Inhibitor Voruciclib At ASH2023	Dec. 11	CI
Earnings Flash (MEIP) MEI PHARMA Posts Q1 Revenue $65.3M	Nov. 09	MT
MEI Pharma, Inc. Reports Earnings Results for the First Quarter Ended September 30, 2023	Nov. 09	CI
MEI Pharma, Inc. Declares Special Cash Dividend of Common Stock, Payable on December 6, 2023	Nov. 06	CI
MEI Pharma Announces Acceptance of Abstract for Presentation at ASH 2023	Nov. 02	CI
MEI Pharma, Anson Funds and Cable Car Capital Enter into Cooperation Agreement	Nov. 01	CI
MEI Pharma, Inc. Announces Board Changes	Nov. 01	CI
MEI Pharma Solicits Proxies from Shareholders	23-10-18	CI
Anson Funds Files Definitive Proxy Statement with Securities and Exchange Commission	23-10-10	CI
Anson Funds hires Legion Partners' Gupta to build out activism strategy	23-10-03	RE
Anson Advisors and Cable Car Capital Withdraws their Consent Solicitation	23-09-29	CI
MEI Pharma Says Consent Solicitation by Anson Advisors, Cable Car Capital Would Create Significant Governance Disruption	23-09-29	MT
MEI Pharma Issues Statement Regarding Anson Advisors and Cable Car?s Actions	23-09-28	CI
Stifel Adjusts Price Target on MEI Pharma to $9 From $10, Maintains Hold Rating	23-09-27	MT
MEI Pharma Rose in After-Hours Activity Tuesday Following Fiscal 2023 Results That Showed Higher Sales, Narrower Net Loss	23-09-27	MT
Transcript : MEI Pharma, Inc., Q4 2023 Earnings Call, Sep 26, 2023	23-09-26
MEI Pharma, Inc. Reports Earnings Results for the Full Year Ended June 30, 2023	23-09-26	CI
Anson Advisors Solicits Proxies from Shareholders of MEI Pharma	23-09-26	CI
North American Morning Briefing : Yield Surge -2-	23-09-26	DJ
MEI Pharma Reports Institutional Purchase of 32,040 Shares Along With 6,000 Put Options	23-09-26	MT

Chart MEI Pharma, Inc.

Duration

Period

More charts

Company Profile

MEI Pharma, Inc. is a clinical-stage pharmaceutical company, which is engaged in developing novel and differentiated cancer therapies. Its drug candidate pipeline includes Voruciclib, an oral cyclin-dependent kinase 9 (CDK9) inhibitor, and ME-344, an intravenous small molecule mitochondrial inhibitor targeting the oxidative phosphorylation pathway. Voruciclib is a potent and selective orally administered CDK9 inhibitor. Voruciclib is being studied in a Phase 1 trial evaluating dose and schedule in patients with acute myeloid leukemia (AML) and B-cell malignancies as a single-agent, and in combination with the B-cell lymphoma 2 (BCL) inhibitor venetoclax (marketed as Venclexta) in patients with AML. ME-344 is a novel mitochondrial inhibitor drug candidate that demonstrates tumor selective activity in pre-clinical studies. It targets the OXPHOS pathway involved in the production of adenosine triphosphate (ATP).

Sector

Biotechnology & Medical Research

Calendar

2024-05-08 - Q3 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Ratings for MEI Pharma, Inc.

Trading Rating

Investor Rating

ESG Refinitiv

B-

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

3.05 USD

Average target price

23 USD

Spread / Average Target

+654.10%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
MEI PHARMA, INC.	-47.41%	20.32M
IQVIA HOLDINGS INC.	+1.51%	42.75B
LONZA GROUP AG	+49.22%	41.61B
MODERNA, INC.	+8.57%	41.34B
CELLTRION, INC.	-12.36%	26.59B
ICON PUBLIC LIMITED COMPANY	+8.92%	25.49B
ALNYLAM PHARMACEUTICALS, INC.	-25.13%	18.12B
MEDPACE HOLDINGS, INC.	+29.17%	12.24B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	-3.12%	11.76B
UNITED THERAPEUTICS CORPORATION	+6.35%	11B

Other Biotechnology & Medical Research